MODERN VIEW ON CARDIOTOXICITY OF CHEMOTHERAPEUTICS IN ONCOLOGY INCLUDING ANTHRACYCLINES

High efficacy of contemporary chemical and radiation treatments made it to success in treatment of oncohematological diseases. The fundamentals of many schemes of polychemotherapy of the first line are anthracyclines. Effective treatment of the main disease in many cases is followed by a variety of...

Full description

Bibliographic Details
Main Authors: G. E. Gendlin, E. I. Emelina, I. G. Nikitin, Yu. A. Vasyuk
Format: Article
Language:Russian
Published: «FIRMA «SILICEA» LLC 2017-03-01
Series:Российский кардиологический журнал
Subjects:
Online Access:https://russjcardiol.elpub.ru/jour/article/view/1609
_version_ 1797856923069972480
author G. E. Gendlin
E. I. Emelina
I. G. Nikitin
Yu. A. Vasyuk
author_facet G. E. Gendlin
E. I. Emelina
I. G. Nikitin
Yu. A. Vasyuk
author_sort G. E. Gendlin
collection DOAJ
description High efficacy of contemporary chemical and radiation treatments made it to success in treatment of oncohematological diseases. The fundamentals of many schemes of polychemotherapy of the first line are anthracyclines. Effective treatment of the main disease in many cases is followed by a variety of cardiovascular  complications, including severe ones and fatal. It is necessary to consider the possibility not only for development  of acute cardiotoxicity, but various complications from cardiovascular system  after cessation of antitumor treatment. Algorithm of patients  preparing  for such treatment must include cardiovascular  assessment before the start of drugs, and follow-up during the treatment course. Prevention and treatment of cardiotoxicity are complicated clinical issues due to irreversible and progressing character of most disorders  of cardiovascular  system.  An important issue  is a close collaboration of cardiologist and oncologist in patient’s management. It is necessary to have longterm  dynamic  follow-up of  patients   after  chemotherapy  for  maximally early diagnostics   of cardiovascular   complications  in long-term  period  after  finishing of antitumor treatment.
first_indexed 2024-04-09T20:48:24Z
format Article
id doaj.art-01285b13faaf47b7a2af93b0a24f1b9f
institution Directory Open Access Journal
issn 1560-4071
2618-7620
language Russian
last_indexed 2024-04-09T20:48:24Z
publishDate 2017-03-01
publisher «FIRMA «SILICEA» LLC
record_format Article
series Российский кардиологический журнал
spelling doaj.art-01285b13faaf47b7a2af93b0a24f1b9f2023-03-29T21:23:27Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202017-03-010314515410.15829/1560-4071-2017-3-145-1541391MODERN VIEW ON CARDIOTOXICITY OF CHEMOTHERAPEUTICS IN ONCOLOGY INCLUDING ANTHRACYCLINESG. E. Gendlin0E. I. Emelina1I. G. Nikitin2Yu. A. Vasyuk3N. I. Pirogov Russian National Research Medical UniversityN. I. Pirogov Russian National Research Medical UniversityN. I. Pirogov Russian National Research Medical UniversityA. I. Evdokimov Moscow State University of Medicine and DentistryHigh efficacy of contemporary chemical and radiation treatments made it to success in treatment of oncohematological diseases. The fundamentals of many schemes of polychemotherapy of the first line are anthracyclines. Effective treatment of the main disease in many cases is followed by a variety of cardiovascular  complications, including severe ones and fatal. It is necessary to consider the possibility not only for development  of acute cardiotoxicity, but various complications from cardiovascular system  after cessation of antitumor treatment. Algorithm of patients  preparing  for such treatment must include cardiovascular  assessment before the start of drugs, and follow-up during the treatment course. Prevention and treatment of cardiotoxicity are complicated clinical issues due to irreversible and progressing character of most disorders  of cardiovascular  system.  An important issue  is a close collaboration of cardiologist and oncologist in patient’s management. It is necessary to have longterm  dynamic  follow-up of  patients   after  chemotherapy  for  maximally early diagnostics   of cardiovascular   complications  in long-term  period  after  finishing of antitumor treatment.https://russjcardiol.elpub.ru/jour/article/view/1609cardiotoxicityanthracyclinescomplications of tumor drug treatmentconsequences of chemical and radiation therapyanthracycline cardiomyopathychronic heart failureprevention and treatment of cardiotoxicity
spellingShingle G. E. Gendlin
E. I. Emelina
I. G. Nikitin
Yu. A. Vasyuk
MODERN VIEW ON CARDIOTOXICITY OF CHEMOTHERAPEUTICS IN ONCOLOGY INCLUDING ANTHRACYCLINES
Российский кардиологический журнал
cardiotoxicity
anthracyclines
complications of tumor drug treatment
consequences of chemical and radiation therapy
anthracycline cardiomyopathy
chronic heart failure
prevention and treatment of cardiotoxicity
title MODERN VIEW ON CARDIOTOXICITY OF CHEMOTHERAPEUTICS IN ONCOLOGY INCLUDING ANTHRACYCLINES
title_full MODERN VIEW ON CARDIOTOXICITY OF CHEMOTHERAPEUTICS IN ONCOLOGY INCLUDING ANTHRACYCLINES
title_fullStr MODERN VIEW ON CARDIOTOXICITY OF CHEMOTHERAPEUTICS IN ONCOLOGY INCLUDING ANTHRACYCLINES
title_full_unstemmed MODERN VIEW ON CARDIOTOXICITY OF CHEMOTHERAPEUTICS IN ONCOLOGY INCLUDING ANTHRACYCLINES
title_short MODERN VIEW ON CARDIOTOXICITY OF CHEMOTHERAPEUTICS IN ONCOLOGY INCLUDING ANTHRACYCLINES
title_sort modern view on cardiotoxicity of chemotherapeutics in oncology including anthracyclines
topic cardiotoxicity
anthracyclines
complications of tumor drug treatment
consequences of chemical and radiation therapy
anthracycline cardiomyopathy
chronic heart failure
prevention and treatment of cardiotoxicity
url https://russjcardiol.elpub.ru/jour/article/view/1609
work_keys_str_mv AT gegendlin modernviewoncardiotoxicityofchemotherapeuticsinoncologyincludinganthracyclines
AT eiemelina modernviewoncardiotoxicityofchemotherapeuticsinoncologyincludinganthracyclines
AT ignikitin modernviewoncardiotoxicityofchemotherapeuticsinoncologyincludinganthracyclines
AT yuavasyuk modernviewoncardiotoxicityofchemotherapeuticsinoncologyincludinganthracyclines